Advanced in Delirium

Jesus A. Caballero

Lleida, CT, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Delirium
Lleida, CT, ES 
OverviewLocationsClinical Research

Overview

Jesus Caballero practices in Lleida, Spain. Mr. Caballero is rated as an Advanced expert by MediFind in the treatment of Delirium. His top areas of expertise are COVID-19, Severe Acute Respiratory Syndrome (SARS), Delirium, and Acute Respiratory Distress Syndrome (ARDS).

His clinical research consists of co-authoring 51 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Delirium.

Gender
Male

Locations

Lleida, CT 25198, Spain
Other Locations
Sevilla, AN 41080, Spain
Barcelona, CT, Spain
Villanueva De La Canada, MD 28692, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

ROX Index Compared to Standard of Care for the Timing of Intubation in Patients Supported by Nasal High Flow: a Randomized Controlled Trial
ROX Index Compared to Standard of Care for the Timing of Intubation in Patients Supported by Nasal High Flow: a Randomized Controlled Trial
Enrollment Status: Recruiting
Publish Date: August 15, 2024
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia
A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia
Enrollment Status: Terminated
Publish Date: June 21, 2022
Intervention Type: Drug, Biological
Study Drugs: Tocilizumab, Pembrolizumab
Study Phase: Phase 2
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Biological, Other
Study Drug: Cx611
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trial

51 Total Publications

First Measurement of the Electron-Neutrino Charged-Current Pion Production Cross Section on Carbon with the T2K Near Detector.
First Measurement of the Electron-Neutrino Charged-Current Pion Production Cross Section on Carbon with the T2K Near Detector.
Journal: Physical review letters
Published: May 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Caballero's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile